Stelis Biopharma to make 200 mn doses of Russia's Sputnik V Covid vaccine

Stelis will commence supplies from September quarter of 2021 and will also continue to work with RDIF to provide additional supply volumes beyond the initial agreement

Bengaluru-headquartered Stelis Biopharma has joined domestic pharmaceutical firms Gland Pharma and Hetero becoming the third Indian company to partner with the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, to produce and supply the Sputnik V vaccine against coronavirus. 

The RDIF-Stelis agreement, which involves the initial production and supply of about 200 million doses of the vaccine, was reached under the aegis of Enso Healthcare, RDIF’s coordination partner for sourcing Sputnik V vaccines in India. 

Stelis will commence supplies from September quarter of 2021 and will also continue to work with RDIF to provide additional supply volumes beyond the